logo
  Join        Login             Stock Quote

DUSA (DUSA) To Be Acquired By India's Sun Pharmaceutical

 November 08, 2012 07:15 AM


(By Balachander) DUSA Pharmaceuticals Inc. (NASDAQ: DUSA), a dermatology company, has agreed to be acquired by India-based Sun Pharmaceutical Industries Ltd. for roughly $230 million in cash or $8.00 a share.

The deal represents a premium of 38 percent to DUSA's previous closing price of $5.78.

"DUSA's business brings us an entry into dermatological treatment devices, where we see good growth opportunities," commented Dilip Shanghvi Managing Director of Sun Pharmaceutical.

DUSA's commercial brands include BLU-U, and Levulan/ Kerastick.

The U.S. FDA approved DUSA's BLU-U to treat moderate inflammatory acne vulgaris and general dermatological conditions.

DUSA shares have been trading in the 52-week range of $3.25 to $7.33.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageDeath Cross More Of A Buy Signal?

With the recent weakness in the equity markets, many stocks' and stock indices' chart patterns have traced read on...

article imageKey Price Planning Levels Updated for Chipotle

After a huge price surge from $600 to $760, Chipotle (CMG) shares retraced to a critical “Make or Break” read on...

article imageChina Growth and Market Structural Integrity Top List of Fear Poll Concerns

After a hiatus of almost a year (the October 2014 pullback, to be exact), I have reprised the VIX and More read on...

article imageIs The Treasury Market Still Expecting Moderate US Growth?

The roller-coaster ride in global markets in recent weeks has raised new doubts about economic growth in read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Recent Articles by Balachander
More Articles on: Medical , India



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.